Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for sevasemten in DMD such as the patient population to be studied, the firm says.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>

>;elm:context_link;itc:0;sec:content-canvas" href="https://www.tipranks.com/screener/top-smart-score-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">See today’s best-performing stocks on TipRanks >>

Read More on EWTX:

Disclaimer & DisclosureReport an Issue

• Edgewise Therapeutics Announces Positive Sevasemten Results

• Morning Movers: Shell ticks higher after denying interest in BP deal

• Edgewise update in line with expectations, says Leerink

• Truist sees ‘slight weakness’ for Edgewise Therapeutics on regulatory feedback

• Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges